Internal Medicine, Medical Oncology · Jackson, MS
NPI
1487659850
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2969 Curran Dr N, Ste 200
Jackson, MS, 39216
Phone (601) 974-5600
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.9M
215,899 services
Medicare patients, 2024
877
Average age 74
Drug cost, 2024
$4.1M
1,576 prescriptions
Company payments, 2025
$1,404
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manubhai S Patel was code J0185 (injection, aprepitant, 1 mg), 18,590 times for 54 patients. In total Manubhai S Patel billed 215,899 services in 171 codes, and Medicare paid $3.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 18,590 | 54 | $1.31 | $24K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 14,256 | 62 | $21.36 | $304K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 13,700 | 13 | $0.06 | $757 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 10,200 | 31 | $43.56 | $444K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 9,360 | 19 | $37.87 | $354K |
| J9299 Injection, nivolumab, 1 mg | Office | 8,840 | 17 | $24.61 | $218K |
| J0897 Injection, denosumab, 1 mg | Office | 6,060 | 34 | $20.31 | $123K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 5,720 | 56 | $34.80 | $199K |
| J9311 Injection, rituximab 10 mg and hyaluronidase | Office | 4,760 | 12 | $29.07 | $138K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 3,920 | 26 | $1.36 | $5,334 |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,720 | 11 | $0.08 | $289 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,721 | 99 | $0.09 | $241 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,010 | 82 | $0.72 | $1,452 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,900 | 17 | $15.82 | $30K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,790 | 22 | $5.81 | $10K |
By year: 2022 $3.2M for 259,086 services; 2023 $2.9M for 211,169 services; 2024 $3.9M for 215,899 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,538 | 447 | $7.48 | $12K |
| 36415 Venipuncture Blood Collection | 1,320 | 427 | $8.47 | $11K |
| 80053 Clinical Chemistry | 1,294 | 409 | $10.11 | $13K |
| 82728 Clinical Chemistry | 344 | 222 | $13.04 | $4,487 |
| 83550 Clinical Chemistry | 325 | 214 | $8.39 | $2,726 |
| 83540 Clinical Chemistry | 325 | 214 | $6.20 | $2,015 |
| 83521 Immunoassay | 246 | 71 | $16.76 | $4,123 |
| 82607 Clinical Chemistry | 149 | 134 | $14.43 | $2,150 |
| 85055 Blood Count | 144 | 79 | $33.47 | $4,819 |
| 82746 Clinical Chemistry | 125 | 119 | $14.01 | $1,751 |
Medicare prescription drug claims, 2024
In 2024, the drug Manubhai S Patel prescribed most often to Medicare patients was Dexamethasone, with 114 prescriptions and refills. In total Manubhai S Patel wrote 1,576 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 114 | 146 | 33 | $2,138 |
| Acyclovir Generic | 98 | 103 | 24 | $917 |
| Letrozole Generic | 84 | 170 | 20 | $1,846 |
| Lenalidomide Generic | 81 | 81 | 13 | $786K |
| Hydroxyurea Generic | 76 | 143 | 22 | $1,595 |
| Prednisone Generic | 72 | 78 | 19 | $457 |
| Abiraterone Acetate Generic | 66 | 66 | Under 11 | $123K |
| Eliquis Apixaban | 50 | 73 | 12 | $42K |
| Gabapentin Generic | 49 | 53 | 16 | $395 |
| Calquence Acalabrutinib Maleate | 44 | 44 | Under 11 | $554K |
| Potassium Chloride Generic | 39 | 59 | 19 | $501 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 38 | 38 | 31 | $943 |
| Tamoxifen Citrate Generic | 35 | 77 | 11 | $872 |
| Ondansetron Odt Ondansetron | 33 | 41 | 17 | $513 |
| Ondansetron Hcl Generic | 32 | 32 | 24 | $270 |
Brand drugs: - claims; generic drugs: 1,262 claims; opioid claims: 87.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manubhai S Patel $1,404 ($1,404 in general payments such as food, travel and fees) from 31 companies. The largest payer was Celgene Corporation with $204.
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation BMY | 9 | $204 |
| Astellas Pharma US Inc 4503.T | 6 | $136 |
| Gilead Sciences, Inc. GILD | 4 | $118 |
| TerSera Therapeutics LLC | 3 | $99.13 |
| Merck Sharp & Dohme LLC MRK | 3 | $79.52 |
| Pfizer Inc. PFE | 4 | $71.35 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $57.52 |
| GlaxoSmithKline, LLC. GSK | 3 | $57 |
| Stemline Therapeutics Inc. | 2 | $41.86 |
| Recordati_rare_diseases_inc. | 2 | $40.72 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.